All relevant data are within the paper and its Supporting Information files.

Introduction {#sec001}
============

Cognitive enhancing drugs (CEDs) are believed to improve cognitive functions such as attention and motivation \[[@pone.0227818.ref001],[@pone.0227818.ref002]\]. They are prescribed for conditions such as dementia, attention deficit hyperactivity disorder (ADHD) and narcolepsy \[[@pone.0227818.ref003], [@pone.0227818.ref001]\]. Further to their prescribed use, off-prescription use of CEDs has been reported, particularly by students during university assessments \[[@pone.0227818.ref004], [@pone.0227818.ref005]\]. Survey data have identified a number of subjective benefits experienced as a result of taking CEDs, such as improved concentration, the ability to study for longer \[[@pone.0227818.ref006]\], increased alertness \[[@pone.0227818.ref007]\], increased focus, productivity and drive \[[@pone.0227818.ref008]\], increased mental stamina or endurance \[[@pone.0227818.ref009]\] and a greater interest in work \[[@pone.0227818.ref010]\]. The reasons for taking CEDs have been found to include the fear of academic failure, the need to meet high work demands, overcoming procrastination and boosting motivation \[[@pone.0227818.ref011], [@pone.0227818.ref012]\]. Beyond these reasons, some individuals may also be self-medicating to treat undiagnosed attention deficit problems that they are experiencing \[[@pone.0227818.ref006], [@pone.0227818.ref012]\]. Although the perceived effects of CEDs in everyday settings have been investigated \[[@pone.0227818.ref013]--[@pone.0227818.ref015]\], the CEDs included in such surveys were either looked at more generally as prescription stimulants or the use of a range of different CEDs was surveyed. Given that modafinil is recognised as the most commonly used CED off-prescription \[[@pone.0227818.ref016]--[@pone.0227818.ref018]\], the research reported in the current paper focused specifically on understanding the user profile and perceived effects of modafinil when taken for non-medicinal purposes.

Modafinil is a mild psychostimulant drug prescribed for narcolepsy \[[@pone.0227818.ref019]\], sleep apnoea, shift worker sleep disorder \[[@pone.0227818.ref020], [@pone.0227818.ref021]\] and ADHD \[[@pone.0227818.ref022]\]. The recommended dose for modafinil is 200mg taken once daily \[[@pone.0227818.ref023]\]. Modafinil has been found to be well-tolerated, with a low incidence of adverse effects and low potential for abuse \[[@pone.0227818.ref024]\]. It is well absorbed, reaching peak plasma concentration between two and four hours following oral administration, and has a half-life of approximately 12--15 hours \[[@pone.0227818.ref025], [@pone.0227818.ref026]\]. Modafinil's mechanism of action, while not yet fully understood, is complex. It is thought to act primarily through noradrenaline (NE) and dopamine (DA) transporter inhibition \[[@pone.0227818.ref027], [@pone.0227818.ref028]\]. It also acts on serotonin, histamine, gamma-aminobutyric acid and glutamate \[[@pone.0227818.ref029]\]. It is believed that modafinil's action on orexin also results in increases in the hypothalamic release of histamine \[[@pone.0227818.ref030]\] and one of the actions of histamine is arousal and wakefulness. Therefore modafinil, when taken at the end of the day or in the evening, may result in an extended period of wakefulness which some individuals may find advantageous, particularly when working towards a pressing deadline. The most common adverse effects of modafinil are headaches, nausea, nervousness, rhinitis, diarrhoea, anxiety and insomnia \[[@pone.0227818.ref027]\]. In rare cases high doses of modafinil may also induce psychosis \[[@pone.0227818.ref031]\]. Modafinil has been found to enhance some aspects of cognitive performance in the laboratory. Gilleen et al. \[[@pone.0227818.ref032]\] administered a 200mg daily dose of modafinil to healthy volunteers over a 10 day period alongside cognitive training. They found that performance on a language learning task, which drew upon attentional, comprehension and working memory processes, was significantly greater in the modafinil group compared with controls. Whilst other studies (e.g., \[[@pone.0227818.ref033]\]), have reported similar effects of modafinil in non-sleep deprived, healthy individuals, these effects may be stronger when baseline performance is lower \[[@pone.0227818.ref034]\]. Differences in baseline performance may also explain the results of Repantis et al.'s \[[@pone.0227818.ref018]\] systematic review of the effects of modafinil in healthy subjects. They found a moderate positive effect for a single dose administration of modafinil on reaction time, divided, sustained and selective attention. However, Battleday and Brem \[[@pone.0227818.ref035]\] suggested that some of the cognitive tests employed may not have been sensitive enough to detect improvements in healthy, non-sleep deprived adults. Repantis et al. \[[@pone.0227818.ref018]\] acknowledged that the cognitively enhancing effects of modafinil are greater in sleep-deprived individuals and that the effects of CEDs depend, to a certain extent, on an individual's baseline performance. Randall, Shneerson and File's \[[@pone.0227818.ref036]\] analysis of the effects of modafinil in healthy students revealed that modafinil only benefitted performance in those with lower IQ, where significant improvements were found in sustained attention, speed of response and visuospatial and constructional ability. It may be that people choose to take modafinil when perceived cognitive demands are high or when their performance may be lowered through some form of impairment such as low baseline levels (i.e. \[[@pone.0227818.ref018]\]), lower IQ (i.e. \[[@pone.0227818.ref036]\]) or through the use of other drugs. In unimpaired individuals, modafinil may have little or no enhancing effects, although the basic testing paradigms used in some laboratory-based studies may not be robust enough to detect modafinil's effects \[[@pone.0227818.ref035]\].

However, the studies reviewed so far have demonstrated the effects of modafinil when measured under laboratory conditions rather than when it is used illicitly, off-prescription, in daily life. Laboratory-based research takes place in controlled environments, providing very useful behavioural, pharmacodynamic and pharmacokinetic information about modafinil use. Nevertheless, off-prescription use of modafinil occurs in uncontrolled environments, often concurrently with other drug use. Drug interactions, dosage levels, perceived effectiveness, motivation and frequency of use and the quality of drugs are all factors which are likely to reflect the real-life experience of modafinil use. Online surveys, therefore, provide important information regarding everyday experience with modafinil that cannot be obtained via laboratory-based research.

Gaining such information is important since, in recent years, health concerns have been raised regarding the off-prescription use of modafinil for cognitive enhancement \[[@pone.0227818.ref037], [@pone.0227818.ref002]\]. Further to these concerns, it appears that modafinil is commonly used for academic study, at least in elite universities in the UK Higher Education sector. For example, one in five students at Oxford University reported the use of modafinil \[[@pone.0227818.ref005]\] and one in ten students at Cambridge University reported the use of either modafinil, Adderall or Ritalin for the purposes of cognitive enhancement \[[@pone.0227818.ref038]\].

Despite these health concerns and reported prevalence rates, there is no published study focused on both the positive and the negative perceived effects of modafinil and how these may be related to patterns of use, use of other drugs and psychiatric diagnosis. Therefore, the survey reported in the current paper sought to address this gap in the literature. The main aim of the study was to investigate the modafinil users' perceived experiences of the drug and how this related to frequency of use. A further aim was to gain a greater understanding of the modafinil user's profile via the collection of demographic information, motivations for using modafinil, how they accessed the drug and to what extent they were aware of the dangers of unsupervised use, such as those relating, for example, to dosage levels and dependency.

Strong associations have been found between CED use and the use of illicit drugs such as cannabis, cocaine, amphetamines and MDMA/ecstasy \[[@pone.0227818.ref039]--[@pone.0227818.ref042]\]. These associations beg the question as to whether illicit drug users are more likely to take CEDs because they are more open to using drugs in general. Therefore, the current study also aimed to investigate concurrent illicit drug use by modafinil users. Modafinil has been found to have mood enhancing effects \[[@pone.0227818.ref043], [@pone.0227818.ref044]\] and has been identified as having therapeutic potential for depression and cocaine dependency \[[@pone.0227818.ref027]\]. The perceived effects of modafinil amongst drug users and people with a psychiatric diagnosis have not, however, been explicitly investigated outside of the laboratory. Thus, a further aim was to investigate the psychiatric status of modafinil users.

Given that modafinil appears to be used most commonly by students \[[@pone.0227818.ref005], [@pone.0227818.ref038]\], when underperformance is likely \[[@pone.0227818.ref018]\] or work demands are high \[[@pone.0227818.ref011]\], it appears that modafinil provides benefits at cognitively demanding times. It seems to offer many potential benefits such as improved attention, speed of response and visuospatial ability \[[@pone.0227818.ref018], [@pone.0227818.ref036]\], yet it also has low incidence of adverse effects \[[@pone.0227818.ref028]\]. Bearing these points in mind, it was hypothesized that 1) more frequent use of modafinil would yield greater perceived benefits and 2) the perceived benefits would outweigh the perceived negative effects (or risks). Additionally, as it appears that modafinil has the effect of ameliorating poor performance, it seemed very plausible to assume that the benefits provided by modafinil cease to be present once the drug has worn off. Therefore, it was also hypothesized that 3) these reported benefits would not persist beyond the immediate use of modafinil. Finally, bearing in mind the mood-enhancing effects of modafinil \[[@pone.0227818.ref043], [@pone.0227818.ref044]\], it was also hypothesised that 4) individuals with a self-declared psychiatric diagnosis would perceive greater benefits of modafinil use compared with those not reporting a psychiatric diagnosis.

Method {#sec002}
======

Respondents {#sec003}
-----------

This study has been ethically approved by the London South Bank University Research Ethics Committee, UREC 1626. Consent was obtained via a consent form found at the start of the online questionnaire. Respondents were only able to proceed with the survey if they clicked on each statement of the consent form. A convenience sample was recruited through online forums (see [S1 File](#pone.0227818.s001){ref-type="supplementary-material"} in the supplementary materials for the advertisement). Bluelight ([http://www.bluelight.org](http://www.bluelight.org/)) and Drugs-Forum ([http://www.drugs-forum.com](http://www.drugs-forum.com/)) were selected as they are platforms for a wide range of drug users. Reddit ([http://www.reddit.com](http://www.reddit.com/)) was selected as it offers specific platforms (sub-Reddits) for discussions of illicit drug and CED use. Members of many of these forums are recreational drug users (and, in some cases, specifically CED users). They, therefore, tend to be well informed about the drugs in question. These forum members, thus, reflect specific populations of drug users. Although seven of the selected sub-Reddits were drug-related, a further four of the selected sub-Reddits were student forums (see [S2 File](#pone.0227818.s002){ref-type="supplementary-material"} in the supplementary materials for the list of sub-Reddits). As there have been many reports of student use of CEDs during assessment periods \[[@pone.0227818.ref003], [@pone.0227818.ref004]\], the Student Room ([http://www.thestudentroom.co.uk](http://www.thestudentroom.co.uk/)) and the student forum sub-Reddits were selected in order to obtain a broader picture of modafinil use than could be obtained through drug user forums alone. Due to the anonymous nature of data collection, however, it was not possible to separate the data collected from these two population samples. The respondents were recruited by posting an advertisement with a link to the survey on all of the forum sites. No reward was offered for their participation.

A total of 404 respondents completed the survey, of whom 117 reported no use of modafinil and 68 reported prescribed (i.e. medical) use. As this study focused on individuals who reported using modafinil and reported choosing to do so specifically for the purposes of cognitive enhancement, the data from both of these types of respondents were removed prior to statistical analysis. Excluding the data obtained from these respondents resulted in a final sample size of 219. Of the sample, 46.1% were in full-time employment, 26.5% were in part-time employment (both paid and unpaid) and 27.4% were unemployed. However, due to the way in which the question was constructed, it was not possible to determine whether any of the unemployed were students.

Materials {#sec004}
---------

The survey was constructed following an analysis of other recent drug and CED-user surveys \[[@pone.0227818.ref045]--[@pone.0227818.ref047]\] and the identification of outstanding questions from the literature regarding motivations for use and access to CEDs \[[@pone.0227818.ref002]\]. Qualtrics^XM^ survey software was used to create the online survey (see [S3 File](#pone.0227818.s003){ref-type="supplementary-material"} in the supplementary materials for the full questionnaire).

After the presentation of an information sheet and consent form, the questionnaire was presented and ended with a debriefing. A maximum of 51 questions were asked, the total number varied according participants' responses, and, as a result, the time to complete the questionnaire ranged between approximately five and 25 minutes. The individual sections of the questionnaire were as follows:

### Demographics {#sec005}

In order to gain a greater insight into the profile of the modafinil user frequenting these forum sites, demographic information was collected. This section consisted of nine questions, covering age, gender, nationality, educational and employment details.

### Psychiatric health and drug use {#sec006}

This section included 22 questions relating to psychiatric diagnosis, psychiatric treatment and drug use history (cannabis, cocaine, amphetamines such as speed, and MDMA/ecstasy). Example questions were "Have you ever been diagnosed with a psychiatric condition?" and "What was the diagnosis?". The term 'psychiatric diagnosis' was used in order to highlight that a formal diagnosis of mental health issues was required and to avoid any cultural or international differences in how the term 'mental health' might have been perceived by respondents. Given that the questions were framed in this way, the term 'psychiatric diagnosis' has continued to be used when reporting the responses to these questions in the Results section. Drug use questions required respondents to indicate, with a yes or no response, lifetime use, use in the last year and attendance at drug and alcohol treatment programmes (e.g. "Have you ever been treated for a drug or alcohol-related problem?").

### Modafinil use {#sec007}

This section included 16 questions on frequency of use, dosage taken, how modafinil was obtained, concurrent use of other drugs, motivations for use, and perceived risks and benefits experienced after taking modafinil. A full list of respondents' reported concurrent use of other drugs can be found in the [S1 Table](#pone.0227818.s005){ref-type="supplementary-material"} of the supplementary data.

Questions regarding modafinil were presented with the brand names Provigil and Modalert to ensure it was not confused with armodafinil which, although similar to modafinil, is a different drug and may have different effects. Armodafinil is the *R*-isomer of racemic modafinil and has been shown to result in higher plasma concentrations of the drug late in the day and so may result in prolonged wakefulness \[[@pone.0227818.ref029]\]. As studies investigating armodafinil have focused primarily on its waking effect, there is a lack of literature focused on its effects on cognition and, to the authors' knowledge, no study has compared the cognitive enhancing effects of armodafinil and modafinil.

A list of 14 known positive effects (or benefits) of modafinil (which included "none") was presented, for example, "increased concentration", "motivation", "clarity of mind", "ability to focus" and "alertness". The list was chosen rather than providing a free text response in order to avoid respondents misinterpreting the nature of what was required by the question and to facilitate data entry and analysis. This list was drawn from previous surveys and reviews of modafinil and other CEDs \[[@pone.0227818.ref018], [@pone.0227818.ref048], [@pone.0227818.ref049]\] and from online forum posts on the Reddit site (<http://www.reddit.com/>). A list of known negative effects (or risks) of modafinil was drawn from the pharmaceutical data sheet for modafinil \[[@pone.0227818.ref023]\]. A total of 24 negative effects (including 'none') was also presented. These included for example, "anxiety", "diarrhoea", "headache", dry mouth" and "insomnia".

Both lists were presented twice, with respondents asked to self-report their experiences with modafinil during two timeframes, namely 'immediate--whilst on the drug' and 'longer-lasting--once the drug has worn off'. All four lists had the option for respondents to select as many items as they felt applied to them, as well as the option to tick 'other' which, if selected, brought the participant to a text box where further effects could be added via keystrokes. A full list of the benefits and risks presented to the respondents, together with their free text data beyond the listed items, can be found in the [S2 Table](#pone.0227818.s006){ref-type="supplementary-material"} of the supplementary materials.

Two further questions about modafinil were included to assess knowledge of recommended dosages, perceptions of harmful use and dependency on modafinil. These were "How much modafinil do you think it is safe to take at any one time?" (with a single response to be chosen from the following options: none, 50mg, 100mg, 200mg, up to 400mg, and more than 400mg), and "Do you feel dependent on modafinil?" (requiring a yes or no response).

Analysis {#sec008}
--------

A mixed-measures design was used to investigate the perceived effects of modafinil and its frequency of use. There was one between-group factor, the frequency of use of modafinil (with five levels: every day, three or more times a week, once or twice a week, two or three times a month and six times or less a year). The two within-group factors were the timeframe over which the effects of modafinil were reported (with two levels: immediate and longer-lasting) and the perceived effects of modafinil (with two levels: benefits and risks). A between-groups design was used to investigate whether reported psychiatric diagnosis status, the dependent variable, had an influence on perceived effects of modafinil, the independent variable.

Data relating to frequency of use of modafinil were analysed using SPSS software, version 21. A three-way mixed-measures analysis of variance (ANOVA) was conducted. Five x 2 x 2 ANOVAs were used to explore the differences between the perceived positive and negative effects of modafinil and how these related to frequency of use. As the highest number of positive effects selected by any respondent was 14 (n = 1) and the highest number of negative effects selected was 7 (n = 1) (not including options of 'none' and 'other'), these data were treated as continuous. The large number of cells with uneven cell sizes would otherwise have prevented a coherent analysis of categorical data. Bonferroni post-hoc tests were used to determine significant differences in the number of effects reported for different frequencies of use. To facilitate the interpretation of a 2 x 5 interaction, post-hoc t-tests were used. Furthermore, Cohen's d was calculated using the mean difference between the groups and dividing this by the pooled standard deviation to determine the size of the difference between positive and negative effects in each frequency of use group.

Mann-Whiney U tests were performed to establish whether psychiatric diagnosis status had any impact on perceived effects of modafinil. For this analysis, the total number of perceived risks was subtracted from the total number of perceived benefits. This created a risk-benefit trade-off value with positive scores indicating that the perceived benefits outweighed the perceived risks. These scores were calculated to enable comparisons to be made between those with and without a reported psychiatric diagnosis.

Procedure {#sec009}
---------

A link to the survey, along with an advertisement, was posted, with appropriate permission, to the selected forum sites. The survey was conducted over a two-month period from August 12th to October 12th, 2016. Respondents were asked to confirm they were aged over 18 years and not under the influence of a psychoactive drug whilst completing the survey. Once the consent form had been clicked to indicate consent, the survey commenced. It ended with a debriefing text which required the selection of a submit button for the data to be logged and included in the analyses.

Results {#sec010}
=======

Demographics {#sec011}
------------

The survey respondents reported themselves to be predominantly male (86%, N = 188) and aged 18--68 years with a mean age of 27 years (SD = 9.85). Over half the respondents were either American (36%, N = 73) or British (27%, N = 54), with European (11%, N = 22), Australian (9%, N = 19), Canadian (6%, N = 13) and 'Other' (11%, N = 21) nationalities also being reported. Less than 1% of the sample indicated that they were educated up to the age of 16 (N = 1) and 37% (N = 80) reported that they were educated up to the age of 18. The remainder reported that they held undergraduate (43%, N = 93) or postgraduate (21%, N = 45) degrees. A total of 54% (N = 118) of respondents reported that they were currently studying for a qualification and 43% (N = 95) reported that they were university students. Therefore, the majority of respondents currently studying (reportedly) said they were university students (80%, N = 95).

Psychiatric diagnosis {#sec012}
---------------------

The proportion of respondents who reported a psychiatric diagnosis was 22% (N = 47). The most commonly reported diagnoses were 'Depression' (10%, N = 21), 'Anxiety' (1%, N = 3), 'Depression with Anxiety' (6%, N = 13) and 'Other' (5%, N = 10).

Illicit drug use {#sec013}
----------------

Cannabis was the most commonly reported illicit drug used by the respondents (lifetime use, 83%, N = 180, past year use, 60%, N = 112), followed by MDMA (lifetime use, 47%, N = 103, 47%, past year use, 29%, N = 49), cocaine (lifetime use, 41%, N = 89, past year use 21%, N = 35) and amphetamines (lifetime use, 46%, N = 98, past year use, 26%, N = 45).

Access to modafinil {#sec014}
-------------------

The respondents were asked to indicate how they obtained modafinil, selecting more than one option if applicable. The most commonly reported means of access was via online sources (78%, N = 170), followed by access via a friend (8%, N = 18), a dealer (7%, N = 16), and someone else's prescription (2%, N = 4). If modafinil was obtained via sources not presented in the survey, the respondents selected 'other' (10%, N = 22) which covered access (such as 'over-the-counter') in a country where it is legal to purchase the drug.

Motivations for use of modafinil {#sec015}
--------------------------------

The most commonly reported motivation for modafinil use was to improve attention/focus (84%, N = 183). The remaining reported motivations for use were 'to work long hours' (54%, N = 119), 'to get more done' (78%, N = 169), 'exams' (33%, N = 71), 'night work' (19%, N = 42), 'to think more clearly' (55%, N = 120), and 'other' (13%, N = 28).

Frequency of modafinil use and perceived risks and benefits of modafinil {#sec016}
------------------------------------------------------------------------

The data analyses reported in this subsection are based on the total number of boxes ticked in the perceived risks and benefits section of the questionnaire. Respondents reporting that they took modafinil on a daily basis reported the greatest number of perceived effects (benefits and risks) across both timeframes (immediate and longer lasting). Means, as well as the minimum and maximum numbers of total effects, are shown in [Table 1](#pone.0227818.t001){ref-type="table"}.

10.1371/journal.pone.0227818.t001

###### Frequency of modafinil use and means for both benefits and risks of modafinil.

![](pone.0227818.t001){#pone.0227818.t001g}

  *Reported frequency of modafinil use*   *N (%)*[\*](#t001fn002){ref-type="table-fn"}   *Mean (SD) overall no*. *of effects*   *Min no*. *of overall effects*[\*\*](#t001fn003){ref-type="table-fn"}   *Max no. of overall effects*[\*\*](#t001fn003){ref-type="table-fn"}
  --------------------------------------- ---------------------------------------------- -------------------------------------- ----------------------------------------------------------------------- ---------------------------------------------------------------------
  **Every day**                           26 (11.90)                                     4.39 (0.27)                            1.00                                                                    8.00
  **Three or more days/ week**            66 (30.10)                                     3.68 (0.17)                            1.25                                                                    8.5
  **Once or twice/week**                  52 (23.70)                                     3.70 (0.19)                            1.25                                                                    7.00
  **Two or three times/month**            38 (17.40)                                     3.17 (0.22)                            1.00                                                                    6.50
  **Six times or fewer per year**         37 (16.90)                                     2.27 (0.22)                            1.00                                                                    4.75

Respondents (N = 219)

\*Percentages relate to the number of respondents within each frequency of use category.

\*\*Effects are collapsed across timeframe and perceived effects, therefore the minimum and maximum numbers reported in the table may not reflect whole numbers.

There was a significant main effect of frequency of modafinil use on the number of effects reported, (*F*~(4,\ 214)~ = 6.91, *MSE* = 7.42, *p* \< .001, η~p~^2^ = .114). Compared with the respondents whose reported modafinil usage was six or fewer times per year, Bonferroni post-hoc tests confirmed significant differences in the number of effects reported between those who reported taking modafinil once or twice per week (*p* = .010), three times or more per week (*p* = .007), and every day (*p* \< .001). A significant difference was also found in the number of effects reported between those respondents who reported taking modafinil two or three times per month and those who reported taking it every day (*p* = .006).

The respondents reported experiencing more immediate effects (mean = 4.99, *SE* = 0.14) than longer-lasting effects (mean = 2.07, *SE* = 0.10) and there was a significant main effect of timeframe of modafinil use, (*F*~(1,\ 214)~ = 465.21, *MSE* = 3.648, *p* \< .001, η~p~^2^ = .685).

The respondents reported more benefits (mean = 5.26, *SE* = 0.17) than risks (mean = 1.80, *SE* = 0.07). There was a significant main effect of perceived effects on modafinil use, (*F*~(4,\ 214)~ = 379.3, *MSE* = 6.264, *p* \< .001, η~p~^2^ = .639).

There was a significant interaction between timeframe and frequency of use of modafinil, (*F*~(4,\ 214)~ = 2.53, *MSE* = 3.648, *p* = .041, η~p~^2^ = .045), see [Fig 1](#pone.0227818.g001){ref-type="fig"}. Post-hoc within-subjects t-tests confirmed that the difference between immediate and longer lasting effects was significant for all five frequency of use groups (see [S3 Table](#pone.0227818.s007){ref-type="supplementary-material"} of the supplementary material for further information). Data presented in the 2 x 2 x 5 ANOVAs were not normally distributed. The results of the ANOVAs run on log transformed data are available in the supplementary materials ([S4 Table](#pone.0227818.s008){ref-type="supplementary-material"}). The overall pattern of the results remained the same after log transformation.

![Interaction between timeframe of perceived effects and frequency of use of modafinil.](pone.0227818.g001){#pone.0227818.g001}

In order to determine the relative magnitude of the differences between the perceived immediate and longer-lasting effects, Cohen's *d* was calculated to establish the effect size for the difference for each frequency of use group. The results indicated that the effect size was smaller for both everyday use and six or fewer times a year than for all other frequency of use groups. The two-way interaction appears, therefore, to be due to a smaller difference between the reported immediate and longer-lasting effects in the most and least frequent use groups. [Fig 1](#pone.0227818.g001){ref-type="fig"} suggests that every day users reported a higher number of long-term effects (risks and benefits combined) and those that reported a frequency of use of six times or fewer reported fewer immediate effects (both risks and benefits combined).

There was a significant interaction between perceived effects and the reported frequency of use of modafinil, (*F*~(4,\ 214)~ = 4.597, *MSE* = 6.264, *p* \< .001, η~p~^2^ = .079), and this is plotted [Fig 2](#pone.0227818.g002){ref-type="fig"}. Post-hoc within-subjects t-tests confirmed that the difference between perceived benefits and risks was significant for all five frequency of use groups (see [S5 Table](#pone.0227818.s009){ref-type="supplementary-material"} of the supplementary material for further information). Cohen's *d* was calculated to establish the effect size for the difference between risks and benefits for each frequency of use group. The effect size was smallest for six or fewer times a year. [Fig 2](#pone.0227818.g002){ref-type="fig"} shows that the reported frequency of use of modafinil of less than once a month yielded a smaller difference between its perceived risks and benefits.

![The interaction between the number of perceived effects and the frequency of use of modafinil.](pone.0227818.g002){#pone.0227818.g002}

Further to this, the interaction between timeframe and perceived effects was also significant, (*F*~(1,\ 214)~ = 313.32, *MSE* = 2.739, *p* \< .001, η~p~^2^ = .594). The immediate benefits were higher than the immediate risks (mean~(benefit)~ = 7.77, SE = 0.24, mean~(risk)~ = 2.22, SE = 0.11, *t* = 22.758, df = 218, *p* \< .001, *d* = 1.54). Longer-lasting benefits were also higher than longer-lasting risks (mean~(benefit)~ = 2.76, SE = 0.17, mean~(risk)~ = 1.38, SE = 0.06, *t* = 8.111, df = 218, *p* \< .001). The effect size for the difference between immediate risks and benefits was higher (*d* = 1.54) than the effect size for longer-lasting risks and benefits (*d* = 0.54).

The three-way interaction between perceived effects, timeframe and frequency of use of modafinil was not statistically significant, (*F*~(4,\ 214)~ = 1.53, *MSE* = 2.739, *p* = .195).

Dosage and dependency {#sec017}
---------------------

Half the respondents (N = 111, 51%) reported that they considered a dose of 200mg of modafinil to be safe to take at any one time, 31.5% (N = 69) felt that a dose of up to 400mg was safe, 11% (N = 23) reported feeling that a dose of more than 400mg was safe, 6% (N = 12) felt that a dose of 100mg was safe and 2% (N = 4) reported feeling that 50mg was a safe dose.

Only 6% (N = 12) of respondents reported feeling dependent on modafinil, all of whom reported taking modafinil at least once or twice a week.

Effects of psychiatric diagnosis on perceived effects of modafinil {#sec018}
------------------------------------------------------------------

The number of the immediate effects of modafinil which were reported differed based on the respondents' reported psychiatric diagnosis status. Individuals who reported a psychiatric diagnosis reported experiencing greater longer-lasting benefits of modafinil than those without a diagnosis (see [Table 2](#pone.0227818.t002){ref-type="table"}).

10.1371/journal.pone.0227818.t002

###### Effects of mental health diagnosis on perceived effects of modafinil.
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                              Yes/No[\*\*\*](#t002fn004){ref-type="table-fn"} (N)   Immediate effects[\*](#t002fn002){ref-type="table-fn"}   Longer-lasting effects[\*](#t002fn002){ref-type="table-fn"}                                  
  --------------------------- ----------------------------------------------------- -------------------------------------------------------- ------------------------------------------------------------- ------- ------------- -------- -------
  **Psychiatric diagnosis**   Yes (48)                                              5.10 (4.01)                                              3737.5                                                        0.343   1.98 (2.88)   3259.0   0.021
  No (171)                    5.65 (3.48)                                           1.16 (2.28)                                                                                                                                           

Respondents (N = 219)

\*Scores reported are a 'risk-benefit' trade off calculated by subtracting the number of negative effects from the number of positive effects.

\*\* M-W = Mann-Whitney U.

\*\*\* Yes/No indicates those who had not reported having had a psychiatric diagnosis.

Discussion {#sec019}
==========

The overall aim of the survey was to investigate the modafinil users' perceived experiences of the drug and how this related to frequency of use. The results indicate that modafinil was perceived as having greater benefits than risks and a greater reported frequency of use was found to result in greater reported benefits. The majority of respondents reported themselves to be male, employed and university-educated. The perceived dependency on modafinil was low, despite 12% of the sample using modafinil every day. Overall, modafinil was seen as being a safe drug, even when taken three times a week or more. Most respondents appeared to be aware of the recommended dose of 200mg. Although perceived dependency on modafinil was low, the link between frequency of use and perceived benefits suggest that there is a possibility that dependency may develop over time.

The data show that more frequent reported use of modafinil led to perceived benefits. It appears that the reported use of modafinil on at least a monthly basis resulted in a higher number of reported benefits whilst reported risks remain low. A plausible explanation could be that more frequent reported use occurs as a consequence of greater perceived benefits since it seems unlikely that continued use would occur without experiencing the benefits of the drug. Chronic drug use is, however, known to lead to tolerance caused, in part, by a reduction in receptor numbers \[[@pone.0227818.ref050]\] but this may not always be the case with modafinil. Nasr, Wendt and Steiner \[[@pone.0227818.ref051]\] reported that long-term use of modafinil in patients with affective disorders did not induce tolerance. Therefore it is plausible that continued, long-term use of modafinil could still provide these perceived benefits.

The data also show that perceived benefits outweigh perceived risks. The respondents reported significantly more benefits than risks. It is known that modafinil is well-tolerated and lacks the undesirable adverse effects of other stimulants \[[@pone.0227818.ref024]\]. It was, therefore, expected that the benefits would outweigh the risks based on the range of potential benefits that it offers, which include enhanced attention, comprehension and working memory \[[@pone.0227818.ref032]\], as well as alertness, vigilance and enhanced executive functions \[[@pone.0227818.ref052]\].

Perceived benefits, however, did persist beyond immediate use of modafinil. Everyday use of modafinil resulted in higher reported longer-lasting effects. While relatively high effect sizes might be expected when exploring differences between immediate and longer-lasting effects of modafinil, it was not expected that there would be a higher reported level of longer-lasting effects in the 'every day' user group. To the authors' knowledge, modafinil has not been found to exhibit any significant positive neuroplastic changes in humans. It was, therefore, expected that modafinil's positive effects would no longer be reported to be experienced when the drug has ceased to be active. This finding may, however, be explained by the pharmacokinetic profile of modafinil. As the half-life of modafinil is approximately 12--15 hours \[[@pone.0227818.ref025], [@pone.0227818.ref026]\], daily use of modafinil would result in a constant, and possibly increasing, plasma concentration of modafinil, which also suggests constant, higher levels of synaptic DA and NE (in addition to other neurotransmitters that are modulated by modafinil). Increased synaptic DA and NE have been associated with improved cognitive function \[[@pone.0227818.ref028], [@pone.0227818.ref053]\]. It would seem reasonable, therefore, to argue that everyday use would lead to greater reported long-term benefits as levels of modafinil would decline to approximately 25% (i.e. two half-lives) by the time the next dose was taken, resulting in increased concentrations of modafinil in the blood. Modafinil has also been found to have an effect on the glutamate receptors of the hippocampus at ascending doses \[[@pone.0227818.ref029]\] and may well have a supportive effect on long-term potentiation and positive neuroplastic changes which could also explain the increase in longer-lasting effects in the 'everyday' user group.

One-fifth of respondents reported having a psychiatric diagnosis and, of these, the most commonly reported diagnoses were depression, anxiety or both depression and anxiety. However, it should be noted that the reported rates of psychiatric diagnosis among modafinil users do seem to be higher than the 18.3% (of adults in the USA) stated in the 2016 National (USA) Survey on Drug Use and Mental Health \[[@pone.0227818.ref054]\]. Prevalence (and official recognition) of psychiatric problems varies by country, gender and age group \[[@pone.0227818.ref055], [@pone.0227818.ref056]\], therefore making direct comparisons difficult. It may be that modafinil use may have preceded the psychiatric diagnosis or it may be that modafinil may have been being used to combat the potential side-effects of prescribed medications.

Individuals with a psychiatric diagnosis did not always perceive greater benefits of modafinil use compared with those without a psychiatric diagnosis. Respondents with a reported psychiatric diagnosis perceived significantly greater longer-lasting benefits but the perceived immediate benefits were not significantly greater. This is somewhat surprising considering the potential mood enhancing effects of modafinil \[[@pone.0227818.ref043]\]. Deficiencies in DA, NE and serotonin are likely to underpin major depressive disorder \[[@pone.0227818.ref057]\]. As modafinil intake results in higher levels of DA, NE, and serotonin \[[@pone.0227818.ref029]\], it is possible (although highly speculative) that the benefits of these drugs for people with a psychiatric diagnosis may be due to poorer functioning of these neurotransmitter systems. A range of cognitive impairments have been reliably associated with depression \[[@pone.0227818.ref058]\] and some anxiety disorders \[[@pone.0227818.ref059]\]. This raises the possibility that modafinil may be used to enhance poorer cognitive performance amongst this population.

As would be expected from recruitment via online drug user forums, levels of reported illicit drug use in the sample were high. Compared with data from the European Monitoring Centre for Drugs and Drug Addiction \[[@pone.0227818.ref060]\] and the National Institute of Drug Abuse \[[@pone.0227818.ref061]\], modafinil users reported levels of drug use that were between 20% (for cocaine) and 50% (for cannabis) higher than one would expect to see amongst the general population of North America and Europe. These findings are consistent with those of Ott and Biller-Andorno \[[@pone.0227818.ref062]\] who reported similar percentages of lifetime illicit drug use to those reported in the current study. Slightly lower rates of illicit drug use amongst Swiss CED users were reported by Maier, Haug and Schaub \[[@pone.0227818.ref040]\]. The findings in the current study may indicate, as suggested earlier, that illicit drug users are more likely to take CEDs since they report being more open to taking drugs in general. Conversely, although the reported illicit drug use in the current study may reflect the drug user forum population from which the sample was drawn, it does suggest that those who take CEDs tend to use recreational drugs as well.

The present study has a number of limitations. As the current data are based on self-reports, it is possible that the presence of demand characteristics have influenced respondents to provide answers in line with what they perceived as being the aims of the study or, perhaps, it may reflect self-justification of respondents' use of modafinil. Additionally, although the gender bias in the sample may reflect a higher propensity of risk-taking behaviour by men \[[@pone.0227818.ref063]\], it may more simply be an artefact of the online forum recruitment methods as users of such forum sites appear typically to be male \[[@pone.0227818.ref064]--[@pone.0227818.ref066]\]. The questionnaire did not include questions on current use of psychiatric medications or other medications which could potentially interact, attenuate or increase the effects of modafinil and other medications. It is difficult, therefore, to assess the benefits of modafinil in those with a psychiatric diagnosis in the absence of this information. Further research is needed to explore whether there is any evidence to indicate that people with a psychiatric diagnosis self-medicating via the off-prescription use of modafinil.

As many respondents were recruited via drug forums, drug-use data from modafinil users are likely to reflect the behaviour of this population sample and may not reflect all modafinil users. However, this population was targeted to gain a greater understanding of how these drugs were experienced and perceived by users themselves. The survey has thus provided important information on the profile of the off-prescription user of modafinil but the data are subject to the usual limitations of online surveys \[[@pone.0227818.ref067], [@pone.0227818.ref068]\], such as a reliance on self-report measures with no check being possible on the identity of the respondent. In addition, this was a self-selecting sample of people who use student, CED user, and drug user online forums. The demographic profile of 'modafinil users' in this study must be interpreted in the light of the demographics of people who use online forums. Whilst these weaknesses must be acknowledged, the current study is comparable with the approach taken in other published studies \[[@pone.0227818.ref045], [@pone.0227818.ref068]\].

A further limitation is that the survey did not include questions testing for attentional problems. This is potentially a concern as it is possible that there may be an element of self-medication by individuals with low baseline levels of DA and NE. Further research is thus warranted to investigate this possibility.

Finally, the survey did not include questions on nicotine and alcohol use, use of other CEDs or routes of administration of modafinil. The authors intend to address these issues in a further study, which will include these questions and will also investigate cognitive and attentional functions both with and without modafinil use.

Conclusion {#sec020}
==========

To the authors' knowledge, this is the first paper to report a detailed survey into the perceived experience of modafinil and the modafinil user's profile. This study has found that, as the reported frequency of modafinil use increased, the number of perceived benefits increased, whilst the number of negative effects remained stable and unchanged. Respondents also reported significantly more benefits than risks and more immediate benefits than longer-lasting benefits. Conversely, those with a reported psychiatric diagnosis perceived greater longer-lasting benefits compared with those without a psychiatric diagnosis. This study has provided insight into the profile of modafinil users who are, in this English language study at least, mostly male, American or British, educated, employed and in their mid-20s. Overall, modafinil was perceived by users as being safe. There was a pattern of reported recreational drug use associated with modafinil use. There was also a tentative link between the reported use of modafinil and the reported presence of psychiatric disorders, largely depression and anxiety.

This paper has, therefore, highlighted a potential concern over the perception of modafinil as a 'safe' drug, even when taken on a weekly or daily basis. Whilst self-reported dependency was low in this sample, the link between perceived benefits and frequency of use suggests that there may be the potential for dependency to develop over time. The possibility that people may be using modafinil as a supportive treatment for a psychiatric diagnosis warrants further explanation from a public health or clinical use perspective. This link may be suggestive of further beneficial effects of modafinil or, more simply, it may reflect insufficient medical treatment for psychiatric disorders in some people. Whichever explanation turns out to be correct, it is clear from this paper that the reported perceptions of modafinil as a safe drug, with more frequent use giving greater benefits, suggests that off-prescription use may well increase in popularity and this may result in dependency in some people.
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Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

5\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#1: General Comments

The authors have presented interesting descriptive data regarding the use of modafinil as a cognitive enhancing medication. The background information given in the introduction was well written and clear.

The aims and hypotheses seem unclear throughout, mostly in the results section, where a series of results is given without much explanation in the introduction or methods about the purpose of these analyses. Apart from the descriptive statistics, the statistical analysis in this paper is unclear. A thorough review of the statistics is required by the authors, making sure that appropriate statistical tests are used for different types of data.

Specific Comments

Introduction

\- Some of the references for modafinil are outdated -- and reference 6 seems incorrect

\- Does the study consider use of armodafinil or just modafinil? Armodafinil is the r-enantiomer of racemic modafinil and often the two are used interchangeably or quite similarly. Can the authors comment on this?

\- The start of the final paragraph on page 7 is repetitive

\- Were the aims and hypotheses made a-priori or post hoc? Was there a primary hypothesis?

Methods

\- The design section describes the statistical methods -- I believe this section should report the study design, not stats used.

\- Why did the authors exclude those who were prescribed modafinil? They could have been prescribed it and still be using it for cognitive enhancement. Additionally, why did people complete the survey if they were not modafinil users -- could they have been past users? I would like to see some information about these people who were excluded as it may be of interest

\- The Analysis section requires further description of the statistical tests performed

\- Under "Procedure" the specific ethics committee details and approval number should be given

Results

\- In Table 1 the authors have presented both benefits and risks together. I think it would be of more interest to separate the effects into the two as it may be different and of interest to readers to present it that way? Can the authors justify their hypothesis here? The hypothesis described in the introduction does not match the presentation of the results here.

\- The statistics used to describe the effects of frequency of use and number of effects are unclear. This is ultimately categorical data which seems to have been initially represented like it is continuous, then a series of comparisons have been made and p values given, but no comparative statistic given. The statistical methods should be better described in the methods and should be clearly reported.

\- At the end of page 15 there are a series of values given as plurals. Perhaps this information would be better placed in a table in the supplementary material if need be.

\- It is unclear how the Cohen's d values listed at the top of page 16 were calculated. Again this appears to be count data, and should not really be converted to mean values. The Cohen's d values reported reflect very large effect sizes, but this is not commented on further.

\- Figures should be used to support the presentation of data to support the main findings. Neither of the figures match hypotheses outlined in the introduction.

Discussion

\- The initial paragraph of the discussion should describe the main results and then start to place them in context of what is known. The discussion of limitations should be saved until later in the discussion section.

\- Again the primary and secondary hypotheses should be outlined clearly here with reference to the results.

\- The authors acknowledge that selection of a sample from groups of people who discuss the use of the drug as a cognitive enhancer online may be different to normal users. Do we know how many people use the drug as a cognitive enhancer?

Reviewer \#2: This is an interesting study on the off-prescription use of modafinil. The data presented here would provide valuable information for considering the pros and cons of modafinil as a cognitive enhancing drug (CED).

The paper is well written in general, but a few modifications would help readers to understand the significance of the data more straightforwardly. Please consider the following points:

1\) Introduction

This section is a little bit too long and the specific topics of modafinil and CEDs in general are mixed together.

For example, after the introduction on modafinil, concomitant use of CEDs (general) and illicit drugs appeared (p. 4, paragraph 2, 'Strong associations...'). Then the story goes on to the effects of modafinil in laboratory settings. After that, problems about studies on CEDs in general appear again (p. 5, the last paragraph, 'However, these studies...' and subsequent paragraphs, p. 6. 'Survey data...', 'Although the perceiver effects of CEDs').

I would like authors to emphasize more straightforwardly (1) why you focused on modafinil, and (2) why you employed an online survey.

2\) Results

2-1) Could you show several typical examples of perceived risks and benefits? This would help readers to determine what kind of benefits and risks the users perceived.

2-2) A total of 15 positive effects and 24 negative effects were listed (p. 11) but the reported numbers of overall effects (both positive and negative) ranged from 2.27 to 4.39 (Table 1). Does this mean the majority of users did not perceive any effects? Am I right? If so, please mention this briefly. Plus, the rationale for combining both positive and negative effects should be explained.

3\) This section is also a little bit too long. To organize this section better, please consider the following points:

3-1) Considerations on the biochemical mechanisms of action of modafinil and their relevance to motivation for use (p. 21, paragraphs 3 and 4, 'Deficiencies in DA, NE...', 'As reported by Cools et al...') are over-speculation and should be more concise. Plus, please consider referring to action on the histaminergic system. This seems important for night-time use of modafinil.

3-2) As the authors mentioned, this study has several limitations, such as gender bias, source of information from drug forums, and lack of questions on attentional problems. In this manuscript, these are scattered in several paragraphs. I think it is better to create a new paragraph and compile these topics. Plus, in my opinion, several important questions were missing, such as status of cigarette smoking, use of other CEDs, and perceived levels of academic achievement. Could you include these limitations?
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Reviewer \#1: Thank you for the opportunity to review this paper again.

I believe that the descriptive statistics are of interest, but I still have some concerns about the analysis methods implemented in this study.

\- The authors state that their hypotheses were generated post hoc, with no apparent hypotheses prior to starting the study. It is unclear, then, how much the findings reported here are subject to Type I error.

\- As the hypotheses were data driven, statements in the discussion like "the first hypothesis... was supported by the data" is a little dishonest, as this then appears to have been an a-priori hypothesis.

\- Other drug users were excluded, including those using armodafinil which is often used interchangeably, including as discussed by users in online forums

\- It would be good in the supplementary documentation to have a copy of the survey and examples of how it was advertised to these forums

\- It would be good to know specifically which subreddits were targeted (in supplementary material)

\- The "design" section at the top of the methods still describes statistical methods, not the study design, which is better described under "Respondents" the "Design" section should say something about online survey etc. not the between group factors (which is still statistical methods, not design)

\- In the calculation of Cohen's d, which SD was used, was it from this or a reference population?

\- The count data used in this study was probably not normally distributed as it was count data, not truly continuous, yet was treated like normally distributed data. Can the authors confirm if the data was somewhat normally distributed?

Reviewer \#2: I appreciate the author\'s effort to revise the manuscript. As a psychologist, I strongly encourage the authors to continue this kind of work.
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Reviewer \#1: No

Reviewer \#2: No

\[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link \"View Attachments\". If this link does not appear, there are no attachment files to be viewed.\]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, <https://pacev2.apexcovantage.com/>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at <figures@plos.org>. Please note that Supporting Information files do not need this step.
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Author response to Decision Letter 1

12 Dec 2019

Dear Dr Hashimoto

Re. Manuscript ID PONE-D-19-19392R1 entitled "The off-prescription use of modafinil: An online survey of perceived risks and benefits"

Thank you for your email on the 1st November detailing the reviewers' comments on the resubmission. We understand that, although you feel the manuscript has merit, it does not fully meet PLOS ONE's publication criteria as it stands. We have carefully read through the points raised by reviewer one and have addressed each point below.

Reviewer \#1: Thank you for the opportunity to review this paper again.

I believe that the descriptive statistics are of interest, but I still have some concerns about the analysis methods implemented in this study.

\- The authors state that their hypotheses were generated post hoc, with no apparent hypotheses prior to starting the study. It is unclear, then, how much the findings reported here are subject to Type I error.

We thank the reviewer for raising these concerns. The aim of this study was to explore if there are any associations between patterns of use and perceived effects of modafinil outside of the laboratory. This is why the questions were phrased in the way they were. As no previous research has focused on this more 'real-world' experience of acute effects of modafinil, it was not possible to generate specific, directional hypotheses prior to the start of data collection. Once data had been collected we decided that the size of the sample and range of responses to the 'number of perceived effects' questions were best analysed using a 5 x 2 x 2 ANOVA. The specific hypotheses that are in this paper were generated based on the selection of this inferential test.

\- As the hypotheses were data driven, statements in the discussion like "the first hypothesis... was supported by the data" is a little dishonest, as this then appears to have been an a-priori hypothesis.

We appreciate the reviewer's point. We did not intentionally mean to mislead and have changed the wording relating to the hypotheses where necessary.

\- Other drug users were excluded, including those using armodafinil which is often used interchangeably, including as discussed by users in online forums

We thank the reviewer for raising this point. We did not exclude people for taking armodafinil. Exclusions were for not taking modafinil as a cognitive enhancer (e.g. people who reported taking MPH) and for taking cognitive enhancers under prescription. For armodafinil in particular, none of our sample reported taking this when asked what other drugs they use alongside modafinil. A full list of the drugs mentioned in response to this question is now available as a supplementary table.

\- It would be good in the supplementary documentation to have a copy of the survey and examples of how it was advertised to these forums

We appreciate the reviewer's point. These have now been added to the supplementary materials (S1 and S3).

\- It would be good to know specifically which subreddits were targeted (in supplementary material)

We, again, appreciate the reviewer's point. This has now been added to the supplementary materials (S2)

\- The "design" section at the top of the methods still describes statistical methods, not the study design, which is better described under "Respondents" the "Design" section should say something about online survey etc. not the between group factors (which is still statistical methods, not design)

The 'design' section has now been removed and, although we considered moving the contents of this section to the 'respondents' section, we felt that this fits better into the analysis section and we have now moved it to the start of the analysis section.

\- In the calculation of Cohen's d, which SD was used, was it from this or a reference population?

We thank the reviewer for asking for this clarification. The following sentence has now been added to the manuscript.

"Cohen's d was calculated using the mean difference between the groups and dividing this by the pooled standard deviation."

\- The count data used in this study was probably not normally distributed as it was count data, not truly continuous, yet was treated like normally distributed data. Can the authors confirm if the data was somewhat normally distributed?

We thank the reviewer, this is a very good point. We have now checked for normality and have log-transformed the data and re-run the analyses. These show the same pattern of effects and we have provided these analyses in tabular form in the supporting materials. As log-transformed data are not so easy for the reader to interpret we have chosen to retain the original analyses in the write-up. However, if the Editor would prefer the log-transformed analyses we are happy to make this amendment.

Reviewer \#2: I appreciate the author\'s effort to revise the manuscript. As a psychologist, I strongly encourage the authors to continue this kind of work.

We thank the reviewer for this kind encouragement.
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31 Dec 2019

The off-prescription use of modafinil: An online survey of perceived risks and benefits

PONE-D-19-19392R2

Dear Dr. Teodorini,

We are pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it complies with all outstanding technical requirements.

Within one week, you will receive an e-mail containing information on the amendments required prior to publication. When all required modifications have been addressed, you will receive a formal acceptance letter and your manuscript will proceed to our production department and be scheduled for publication.

Shortly after the formal acceptance letter is sent, an invoice for payment will follow. To ensure an efficient production and billing process, please log into Editorial Manager at <https://www.editorialmanager.com/pone/>, click the \"Update My Information\" link at the top of the page, and update your user information. If you have any billing related questions, please contact our Author Billing department directly at <authorbilling@plos.org>.

If your institution or institutions have a press office, please notify them about your upcoming paper to enable them to help maximize its impact. If they will be preparing press materials for this manuscript, you must inform our press team as soon as possible and no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact <onepress@plos.org>.

With kind regards,

Kenji Hashimoto, PhD

Section Editor

PLOS ONE

Additional Editor Comments (optional):

Reviewers\' comments:

Reviewer\'s Responses to Questions

**Comments to the Author**

1\. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the "Comments to the Author" section, enter your conflict of interest statement in the "Confidential to Editor" section, and submit your \"Accept\" recommendation.

Reviewer \#2: All comments have been addressed

\*\*\*\*\*\*\*\*\*\*

2\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

3\. Has the statistical analysis been performed appropriately and rigorously?

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

4\. Have the authors made all data underlying the findings in their manuscript fully available?

The [PLOS Data policy](http://www.plosone.org/static/policies.action#sharing) requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

5\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

6\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#2: The results described here are valuable information for considering promoting mental health of college students. I agree to the authors\' conclusion that we should have a potential concern over the perception of modafinil as a \"safe drug\".

\*\*\*\*\*\*\*\*\*\*

7\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#2: Yes: Naoyuki Hironaka
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14 Jan 2020

PONE-D-19-19392R2

The off-prescription use of modafinil: An online survey of perceived risks and benefits

Dear Dr. Teodorini:

I am pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please notify them about your upcoming paper at this point, to enable them to help maximize its impact. If they will be preparing press materials for this manuscript, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact <onepress@plos.org>.

For any other questions or concerns, please email <plosone@plos.org>.

Thank you for submitting your work to PLOS ONE.

With kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Prof. Kenji Hashimoto

Section Editor

PLOS ONE
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